Protein binding of disopyramide--displacement by mono-N-dealkyldisopyramide and variation with source of alpha-1-acid glycoprotein

The binding of disopyramide to human serum proteins and human alpha-1-acid glycoprotein (AAG) was determined over a wide drug concentration range. Addition of 3.7 X 10(-6) mol litre-1 mono-N-dealkyldisopyramide caused a 20-100% increase in disopyramide free fraction. The disopyramide free fraction i...

Full description

Saved in:
Bibliographic Details
Published inJournal of pharmacy and pharmacology Vol. 37; no. 4; p. 285
Main Authors Haughey, D B, Steinberg, I, Lee, M H
Format Journal Article
LanguageEnglish
Published England 01.04.1985
Subjects
Binding, Competitive - drug effects
Disopyramide - analogs & derivatives
Disopyramide - blood
Disopyramide - metabolism
Disopyramide - pharmacology
Humans
Kinetics
Orosomucoid - metabolism
Protein Binding - drug effects
Online AccessGet more information

Cover

More Information
Summary:The binding of disopyramide to human serum proteins and human alpha-1-acid glycoprotein (AAG) was determined over a wide drug concentration range. Addition of 3.7 X 10(-6) mol litre-1 mono-N-dealkyldisopyramide caused a 20-100% increase in disopyramide free fraction. The disopyramide free fraction in AAG solutions prepared from various commercially available sources of alpha-1-acid glycoprotein varied up to 2.5 fold at corresponding disopyramide concentrations. Pronounced differences in the calculated binding constants (affinity and capacity) were observed among the commercially available AAG preparations. These findings suggest that binding studies should be performed in appropriately harvested human serum or plasma to avoid possible artifacts associated with the use of commercial preparations of alpha-1-acid glycoprotein for binding studies.
ISSN:0022-3573
DOI:10.1111/j.2042-7158.1985.tb05066.x